Skip to Content

Deadline: Open until filled.
Timo Minssen, Director of CeBIL

Read full call

About the programme

Supported by a research grant of DKK 35 million from the Novo Nordisk Foundation, the  Collaborative Research Programme in Biomedical Innovation Law (CeBIL) will address and scrutinize the most significant legal challenges to biomedical innovation and public health from a holistic cross-disciplinary perspective.

The overall aim and ambition of CeBIL is to contribute to the translation of groundbreaking biomedical research into safe, effective, affordable and accessible therapies by analyzing the most significant legal challenges to pharmaceutical innovation and public health from a holistic cross-disciplinary perspective.

PhD Topics

CeBIL welcomes research proposals on legal issues with regard to biomedical technology and innovation, such as:

  • Trade secrets (all topics with a focus on the Health & Life Sciences)
  • Artificial Intelligence, Big Data  
  • Data protection & Clinical Trials
  • E-Health & Internet of things
  • Blockchain technology & tech transfer
  • Reproductive technologies
  • Gene editing & Ethical/ELSI issue
  • Competition Law
  • Rare and neglected diseases
  • Biologics & biosimilars
  • Precision Medicine
  • Patents
  • Data base protection
  • Patient rights
  • Human rights & access to medicine
  • Copyrights
  • Regulatory Exclusivities

Read more about the PhD programme and apply here!

Tags

bioethics   health law policy   innovation